The Philippines faces a unique healthcare paradox. It has one of the world’s youngest populations, yet is experiencing hypergrowth of undiagnosed chronic conditions such as obesity, diabetes, and hypertension. Deeply rooted religious traditions, stigma around sensitive conditions, low health awareness, and a consumption-driven culture compound the problem. The result: millions of Filipinos delay or avoid seeking care altogether, and many serious conditions go undiagnosed.

The healthcare system has struggled to keep pace. Physical infrastructure is underdeveloped, and the regulatory framework for digital health remains nascent. At the same time, the country produces some of the world’s best-trained doctors and nurses—many of whom emigrate overseas, further straining domestic access.

Yet change is underway. Younger Filipinos are more secular, open to breaking through stigma, and embrace telehealth and direct-to-consumer brands. This generational shift presents an inflection point: the opportunity to build trusted, personalized care brands for conditions that have long gone untreated.

This is the opportunity GoRocky is seizing. Founded in 2022 by Kiyanusch Braun and Joaqui Palana, and joined by seasoned operator Paul Robb, the company started with men’s health and hair loss—stigmatized but high-demand entry points. In 2024, GoRocky launched its weight management vertical, which has since become its fastest-growing category and a natural gateway into chronic disease care. By mid-2025, GoRocky had already served over 30,000 patients, facilitated more than 70,000 health assessments, and built repeat engagement rates of over 60% across its categories—clear evidence of both demand and trust.

The team’s execution has impressed us: fast, disciplined, and relentlessly data-driven. What they are building is not just a consumer brand, but a foundational health platform made up of three reinforcing layers. At the front end, a seamless consumer experience makes it easy for patients to take assessments, consult with doctors, and manage ongoing care. Behind this sits the clinical and compliance backbone—telehealth, diagnostics, EMR, e-prescriptions, and systems being continuously enhanced to align with evolving data privacy and regulatory standards. Underpinning both is a data and fulfillment engine that manages logistics, integrates with partners, and continuously learns from every interaction to improve personalization and outcomes.

Together, these layers create a flywheel: a trusted brand drives more patient interactions; more interactions generate richer data and insights; richer data enables better personalization and care delivery; and better outcomes reinforce trust and attract more patients. This cycle makes the platform smarter, more efficient, and more defensible with every use.

We see clear growth vectors ahead, all enabled by this platform architecture. While GoRocky began with men’s health, the same infrastructure can power a companion brand for women—already a growing customer base, especially in weight management. Beyond gender, the platform is well-suited to expand into adjacent verticals such as cardiovascular health, hypertension and diabetes, dermatology, mental health, wellness, and longevity, where personalization and trust matter as much as access. Finally, because many of the same structural drivers—stigma, fragmented care, and demand for consumer-first health brands—exist across Southeast Asia, the model has the potential to extend well beyond the Philippines.

Global peers like Hims & Hers have proven the power of consumer-led digital health. In just nine years, the company has grown into a $12 billion business, still compounding at ~75% year-on-year—a testament to the gravitational pull of a new way of building and delivering personalized care. GoRocky is going further: adapting the model to the realities of the Philippines and Southeast Asia, where the gaps are larger, the cultural barriers higher, and the potential for impact greater. In a market where both access and affordability of healthcare are pressing problems, a direct to patient, personalized care approach may just positively align incentives for patients, providers, and payors alike.

For Integra, this investment is about conviction in a team that has demonstrated rare velocity and capital efficiency, and about mission—expanding affordability and access to care for conditions that millions of Filipinos face but few dare to address. We are proud to back Kiya, Joaqui, and Paul as they build the backbone for chronic care in Southeast Asia.